Portolan Capital Management’s Douglas Elliman DOUG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.25M Sell
2,399,364
-269,666
-10% -$483K 0.16% 123
2026
Q1
$4.38M Buy
2,669,030
+315,080
+13% +$730K 0.23% 108
2025
Q4
$5.58M Hold
2,353,950
0.3% 99
2025
Q3
$6.73M Buy
2,353,950
+521,959
+28% +$1.37M 0.36% 80
2025
Q2
$4.25M Buy
+1,831,991
New +$3.91M 0.27% 95
2025
Q1
Sell
-143,000
Closed -$239K 122
2024
Q4
$239K Sell
143,000
-2,767,906
-95% -$5.32M 0.02% 131
2024
Q3
$5.33M Buy
+2,910,906
New +$4.99M 0.39% 80
2024
Q2
Sell
-2,215,469
Closed -$3.5M 123
2024
Q1
$3.5M Buy
2,215,469
+278,314
+14% +$570K 0.27% 101
2023
Q4
$5.71M Buy
1,937,155
+824,690
+74% +$1.73M 0.5% 71
2023
Q3
$2.51M Sell
1,112,465
-34,514
-3% -$79.3K 0.24% 103
2023
Q2
$2.55M Buy
+1,146,979
New +$3.15M 0.23% 100

Other funds holding DOUG

Portolan Capital Management's DOUG Position: Q2 2026 in Review

Portolan Capital Management reduced its Douglas Elliman (DOUG) stake by 10% in Q2 2026, selling an estimated $483K and leaving 2,399,364 shares worth $4.25M. The position accounts for 0.16% of the portfolio, ranked #123.

Portolan Capital Management first reported a position in DOUG in Q2 2023 and has held it in 11 quarters since. The position peaked at $6.73M in Q3 2025. 132 funds tracked by Wall St. Rank hold DOUG as of Q2 2026.

  • Portolan Capital Management held 2,399,364 shares of Douglas Elliman worth $4.25M as of Q2 2026.
  • Portolan Capital Management sold 269,666 Douglas Elliman shares in Q2 2026, an estimated $483K.
  • Douglas Elliman made up 0.16% of Portolan Capital Management's portfolio in Q2 2026, its #123 holding.
  • Portolan Capital Management first reported a position in Douglas Elliman in Q2 2023 and has held it in 11 quarters since.
  • Portolan Capital Management's Douglas Elliman position peaked at $6.73M in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Douglas Elliman as of Q2 2026.

Based on Portolan Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.